RE:RE:RE:RE:RE:RE:Feb 24, 2017 Pulmonary Fibrosis News IPF - ProMetic
Red... I was under the impression that close to 25% of IPF patients are unable to take either of the standard care treatments because of the severity of the side effects. This not only represents a considerable opportunity in its own right, but should make patients fairly readilly available for the trial wouldnt it ?
On a separate note, I asked what I thought was a simple question to Fred recently. I merely queried whether they considered keeping the mono and combo 1 therapy patients on the drug , given the fairly impressive results. Not only would there seem to be compassionate grounds, but also it seems there would be considerable value in determining whether there is continuity of the actual improvment in FVC
regards